Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
Trial details
- Registry ID
- NCT04804605
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Roflumilast
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic DermatitisNCT04804605 | ARQT | Phase 3 | Completed | 2024-05-28Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |